Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 1/2018

Open Access 01-07-2018 | Epidemiology

The risk of cardiovascular disease following breast cancer by Framingham risk score

Authors: Sofie A. M. Gernaat, Jolanda M. A. Boer, Desiree H. J. van den Bongard, Angela H. E. M. Maas, Carmen C. van der Pol, Rhodé M. Bijlsma, Diederick E. Grobbee, Helena M. Verkooijen, Petra H. Peeters

Published in: Breast Cancer Research and Treatment | Issue 1/2018

Login to get access

Abstract

Objectives

This study evaluates the risk of cardiovascular disease (CVD) following breast cancer, accounting for baseline CVD risk.

Methods

Within the EPIC-NL (Dutch part of the European Prospective Investigation into Nutrition and Cancer) cohort, 1103 women were diagnosed with breast cancer. For every breast cancer patient, 3–4 women without breast cancer (n = 4328) were selected matched for age, year, and time since cohort enrollment. Based on CVD risk factors at cohort enrollment, 10-year risk of CVD was calculated and categorized: low (< 10%), intermediate (10–20%), high (> 20%). Cox proportional hazard models assessed the risk of CVD events (hospitalization or mortality) and CVD mortality of women with versus without breast cancer, adjusted for baseline CVD risk.

Results

After median follow-up of 5 and 6 years, 92 (8.3%) and 325 (7.5%) CVD events occurred in women with and without breast cancer, respectively. In the low CVD risk group, women with breast cancer had 1.44 (95% CI 1.00–2.06) times higher risk of CVD events than women without breast cancer. In the intermediate and high CVD risk categories, risk of CVD events was similar in women with and without breast cancer. Overall, women with breast cancer had 1.77 (95% CI 1.10–2.86) times higher risk of CVD mortality than women without breast cancer.

Conclusions

Among women with low CVD risk, women with breast cancer have a higher risk of CVD event than women without breast cancer. Overall, women with breast cancer have a higher risk of CVD mortality than women without breast cancer.
Appendix
Available only for authorised users
Literature
1.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2014) GLOBOCAN 2012 v1.1, Cancer incidence and mortality worldwide: IARC cancer base. International Journal of Cancer 136(5):359–386CrossRef
2.
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C et al (2016) Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study. JAMA Oncology 3(4):524–548CrossRef
3.
Myers ER, Moorman P, Gierisch JM et al (2015) Benefits and harms of breast cancer screening: A Systematic review. JAMA 314:1615–1634CrossRefPubMed
4.
Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. New England Journal of Medicine 353:1784–1792CrossRefPubMed
5.
Hanrahan EO, Gonzalez-Angulo AM, Giordano SH et al (2007) Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma. Journal of Clinical Oncology 25:4952–4960CrossRefPubMed
6.
Chapman JA, Meng D, Shepherd L et al (2008) Competing causes of death from a randomized trial of extended adjuvant endocrine therapy for breast cancer. Journal of the National Cancer Institute 100:252–260CrossRefPubMedPubMedCentral
7.
8.
Colzani E, Liljegren A, Johansson AL et al (2011) Prognosis of patients with breast cancer: Causes of death and effects of time since diagnosis, age, and tumor characteristics. Journal of Clinical Oncology 29:4014–4021CrossRefPubMed
9.
EBCTCG (Early Breast Cancer Trialists’ Collaborative Group), McGale P, Taylor C et al (2014) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials. The Lancet 383:2127–2135CrossRef
10.
McGale P, Darby SC, Hall P et al (2011) Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiotherapy and Oncology 100:167–175CrossRefPubMed
11.
Clarke M, Collins R, Darby S et al (2005) Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials. The Lancet 366:2087–2106CrossRef
12.
Dalfardi B, Kashy-Zonouzy K, Asvadi-Kermani T (2014) Chemotherapy-induced cardiomyopathy in breast cancer patients. Research in Cardiovascular Medicine 3:e19096CrossRefPubMedPubMedCentral
13.
Chavez-MacGregor M, Zhang N, Buchholz TA et al (2013) Trastuzumab-related cardiotoxicity among older patients with breast cancer. Journal of Clinical Oncology 31:4222–4228CrossRefPubMedPubMedCentral
14.
Pinder MC, Duan Z, Goodwin JS et al (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. Journal of Clinical Oncology 25:3808–3815CrossRefPubMed
15.
Darby SC, Bronnum D, Correa C et al (2010) A dose-response relationship for the incidence of radiation-related heart disease. Journal International Journal of Radiation Oncology Biology Physics 78:S49–S50CrossRef
16.
Rehammar JC, Jensen MB, McGale P et al (2017) Risk of heart disease in relation to radiotherapy and chemotherapy with anthracyclines among 19,464 breast cancer patients in Denmark, 1977-2005. Radiotherapy and Oncology 123:299–305CrossRefPubMedPubMedCentral
17.
Smith LA, Cornelius VR, Plummer CJ et al (2010) Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials. BMC Cancer 10:337CrossRefPubMedPubMedCentral
18.
19.
20.
Jawa Z, Perez RM, Garlie L et al (2016) Risk factors of trastuzumab-induced cardiotoxicity in breast cancer: A meta-analysis. Medicine (Baltimore) 95:e5195CrossRef
21.
Hooning MJ, Botma A, Aleman BM et al (2007) Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. Journal of the National Cancer Institute 99:365–375CrossRefPubMed
22.
McCullough ML, Gapstur SM, Shah R et al (2016) Pre- and postdiagnostic diet in relation to mortality among breast cancer survivors in the CPS-II Nutrition Cohort. Cancer Causes and Control 27(11):1303–1314CrossRefPubMed
23.
Nichols HB, Trentham-Dietz A, Egan KM et al (2009) Body mass index before and after breast cancer diagnosis: Associations with all-cause, breast cancer, and cardiovascular disease mortality. Cancer Epidemiology Biomarkers Prevention 18:1403–1409CrossRef
24.
D’Agostino RBS, Vasan RS, Pencina MJ et al (2008) General cardiovascular risk profile for use in primary care: The Framingham Heart Study. Circulation 117:743–753CrossRefPubMed
25.
Bingham S, Riboli E (2004) Diet and cancer: The European prospective investigation into cancer and nutrition. Nature Reviews Cancer 4:206–215CrossRefPubMed
26.
Beulens JW, Monninkhof EM, Verschuren WM et al (2010) Cohort profile: The EPIC-NL study. International Journal of Epidemiology 39:1170–1178CrossRefPubMed
27.
Smit HA, Verschuren W, Bueno-de-Mesquita HB (1994) Seidell JC. Doelstellingen en werkwijze, Monitoring van Risicofactoren en Gezondheid in Nederland (MORGEN-project), p 263200001
28.
Boker LK, van Noord PA, van der Schouw YT et al (2001) Prospect-EPIC Utrecht: Study design and characteristics of the cohort population. European Prospective Investigation into Cancer and Nutrition. European Journal of Epidemiology 17:1047–1053CrossRefPubMed
29.
Haftenberger M, Schuit AJ, Tormo MJ et al (2002) Physical activity of subjects aged 50-64 years involved in the European Prospective Investigation into Cancer and Nutrition (EPIC). Public Health Nutr 5:1163–1176CrossRefPubMed
30.
Wareham NJ, Jakes RW, Rennie KL et al (2003) Validity and repeatability of a simple index derived from the short physical activity questionnaire used in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. Public Health Nutrition 6:407–413CrossRefPubMed
31.
InterAct Consortium, Peters T, Brage S et al (2012) Validity of a short questionnaire to assess physical activity in 10 European countries. European Journal of Epidemiology 27:15–25CrossRef
32.
Ocke MC, Bueno-de-Mesquita HB, Goddijn HE et al (1997) The Dutch EPIC food frequency questionnaire. I. Description of the questionnaire, and relative validity and reproducibility for food groups. International Journal of Epidemiology 26(Suppl 1):S37–S48CrossRefPubMed
33.
Ocke MC, Bueno-de-Mesquita HB, Goddijn HE et al (1997) The Dutch EPIC food frequency questionnaire II. Relative validity and reproducibility for nutrients. International Journal of Epidemiology 26(Suppl 1):S49–S58CrossRefPubMed
34.
Schulze MB, Kroke A, Saracci R et al (2002) The effect of differences in measurement procedure on the comparability of blood pressure estimates in multi-centre studies. Blood Press Monitoring 7:95–104CrossRef
35.
Herings RM, Bakker A, Stricker BH et al (1992) Pharmaco-morbidity linkage: A feasibility study comparing morbidity in two pharmacy based exposure cohorts. Journal of Epidemiology and Community Health 46:136–140CrossRefPubMedPubMedCentral
36.
van der Heijden GJ, Donders AR, Stijnen T et al (2006) Imputation of missing values is superior to complete case analysis and the missing-indicator method in multivariable diagnostic research: A clinical example. Journal of Clinical Epidemiology 59:1102–1109CrossRefPubMed
37.
Cox DR (1972) Regression models and life-tables. Journal of the Royal Statistical Society 34:187–202
38.
Fine JPGR (1999) A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association 94:496–509CrossRef
39.
Gernaat SAM, Ho PJ, Rijnberg N et al (2017) Risk of death from cardiovascular disease following breast cancer: A systematic review. Breast Cancer Research Treatment 26:S49
40.
Hooning MJ, Aleman BM, van Rosmalen AJ et al (2006) Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study. International Journal of Radiation Oncology Biology Physics 64:1081–1091CrossRef
41.
Schairer C, Mink PJ, Carroll L et al (2004) Probabilities of death from breast cancer and other causes among female breast cancer patients. Journal of the National Cancer Institute 96:1311–1321CrossRefPubMed
42.
Zaorsky NG, Churilla TM, Egleston BL et al (2016) Causes of death among cancer patients. Annals of Oncology 28(2):400–407PubMedCentral
43.
Doyle JJ, Neugut AI, Jacobson JS et al (2005) Chemotherapy and cardiotoxicity in older breast cancer patients: A population-based study. Journal of Clinical Oncology 23:8597–8605CrossRefPubMed
44.
Early Breast Cancer Trialists’ Collaborative Group (2005) (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. The Lancet 365:1687–1717CrossRef
45.
Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New England Journal of Medicine 344:783–792CrossRefPubMed
46.
Vejpongsa P, Yeh ET (2014) Prevention of anthracycline-induced cardiotoxicity: Challenges and opportunities. Journal of the American College of Cardiology 64:938–945CrossRefPubMed
47.
Vasu S, Hundley WG (2013) Understanding cardiovascular injury after treatment for cancer: An overview of current uses and future directions of cardiovascular magnetic resonance. Journal of Cardiovascular Magnetic Resonance 15(1):66CrossRefPubMedPubMedCentral
48.
Omarini C, Thanopoulou E, Johnston SR (2014) Pneumonitis and pulmonary fibrosis associated with breast cancer treatments. Breast Cancer Research Treatment 146:245–258CrossRefPubMed
49.
Yeh ET, Bickford CL (2009) Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management. Journal of the American College of Cardiology 53:2231–2247CrossRefPubMed
50.
Hooning MJ, Dorresteijn LD, Aleman BM et al (2006) Decreased risk of stroke among 10-year survivors of breast cancer. Journal of Clinical Oncology 24:5388–5394CrossRefPubMed
51.
Nilsson G, Holmberg L, Garmo H et al (2005) Increased incidence of stroke in women with breast cancer. European Journal of cancer 41:423–429CrossRefPubMed
52.
Onwudiwe NC, Kwok Y, Onukwugha E et al (2014) Cardiovascular event-free survival after adjuvant radiation therapy in breast cancer patients stratified by cardiovascular risk. Cancer Medicine 3:1342–1352CrossRefPubMedPubMedCentral
53.
Riihimaki M, Thomsen H, Brandt A et al (2012) Death causes in breast cancer patients. Annals of Oncology 23:604–610CrossRefPubMed
54.
Roychoudhuri R, Robinson D, Putcha V et al (2007) Increased cardiovascular mortality more than fifteen years after radiotherapy for breast cancer: A population-based study. BMC Cancer 7:9CrossRefPubMedPubMedCentral
55.
Darby SC, McGale P, Taylor CW et al (2005) Long-term mortality from heart disease and lung cancer after radiotherapy for early breast cancer: Prospective cohort study of about 300,000 women in US SEER cancer registries. The Lancet Oncology 6:557–565CrossRefPubMed
56.
Tsao CW, Vasan RS (2015) Cohort Profile: The Framingham Heart Study (FHS): Overview of milestones in cardiovascular epidemiology. International Journal of Epidemiology 44:1800–1813CrossRefPubMedPubMedCentral
57.
58.
Armenian SH, Lacchetti C, Barac A et al (2017) Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology 35:893–911CrossRefPubMed
59.
Merry AH, Boer JM, Schouten LJ et al (2009) Validity of coronary heart diseases and heart failure based on hospital discharge and mortality data in the Netherlands using the cardiovascular registry Maastricht cohort study. European Journal of Epidemiology 24:237–247CrossRefPubMed
Metadata
Title
The risk of cardiovascular disease following breast cancer by Framingham risk score
Authors
Sofie A. M. Gernaat
Jolanda M. A. Boer
Desiree H. J. van den Bongard
Angela H. E. M. Maas
Carmen C. van der Pol
Rhodé M. Bijlsma
Diederick E. Grobbee
Helena M. Verkooijen
Petra H. Peeters
Publication date
01-07-2018
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 1/2018
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-018-4723-0

Other articles of this Issue 1/2018

Breast Cancer Research and Treatment 1/2018 Go to the issue

Epidemiology

Survival of breast cancer patients in rural Ethiopia

Brief Report

Characterization of a novel breast cancer cell line derived from a metastatic bone lesion of a breast cancer patient

Correction

Correction to: Association between lifestyle, menstrual/reproductive history, and histological factors and risk of breast cancer in women biopsied for benign breast disease

Clinical trial

Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients

Clinical trial

Taste and smell perception and quality of life during and after systemic therapy for breast cancer

Epidemiology

Factors influencing survival among patients with HER2-positive metastatic breast cancer treated with trastuzumab
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits